To conduct a systematic review and meta-analysis to determine the risk of cardiovascular events and all-cause mortality associated with sulphonylureas (SUs) vs other glucose lowering drugs in patients with T2DM (T2DM).
| INTRODUCTION
Type 2 diabetes mellitus (T2DM) is known to increase the risk of cardiovascular disease, with a 2-to 5-fold increased risk of lifethreatening events, such as acute myocardial infarction (MI) and stroke. 1, 2 Recent trials have shown that glucose-lowering treatments may have different, sometimes divergent, effects on cardiovascular risk. 3 Sulphonylureas (SUs) are among the most commonly used treatments for patients with T2DM, yet their long-term safety and their effects on cardiovascular outcomes remain uncertain and controversial. 4 The possibility that SUs increase cardiovascular risk is based on proposed direct effects of SUs on myocardium, [5] [6] [7] [8] and indirect effects of SUs on cardiovascular function. [9] [10] [11] Adequately designed and prospectively conducted RCTs to evaluate the effect of SUs on cardiovascular events compared with other commonly prescribed antihyperglycaemic drugs have not yet been completed. Several systematic reviews and meta-analyses have compared SUs with a variety of antihyperglycaemic drugs; however, the findings of these studies are inconsistent. This may be attributable to differences in study selection and statistical techniques used to analyse the data. [12] [13] [14] [15] [16] [17] [18] [19] Using advanced meta-analytical techniques, the aim of the present study was to assess the risk of cardiovascular-related outcomes associated with SUs vs other antihyperglycaemic drugs using data from RCTs and comparative observational studies. Analyses of survival data were performed separately for both RCT evidence and observational evidence to facilitate a multi-level inference approach.
| MATERIALS AND METHODS

| Overview
We conducted a systematic literature review to identify studies that compared SU monotherapy or an SU in combination with another antihyperglycaemic drug against placebo/no intervention or other antihyperglycaemic drugs. Data derived from the studies identified in the systematic literature review were used to compare the risk of cardiovascular events associated with the use of SUs and the other selected treatments.
| Eligibility criteria
The eligibility criteria used to select studies in the systematic literature review are presented according to the population, intervention, control, outcomes, study design (PICOS) convention (Table S1 ). In brief, RCTs and non-randomized comparative studies, including prospective or retrospective observational cohort studies and casecontrol studies, conducted among adult patients diagnosed with T2DM who were either treatment-naïve or had previous exposure to antihyperglycaemic drugs were eligible for inclusion. 
| Literature search
A systematic search of the peer-reviewed literature was conducted in
Medline, Embase and the Cochrane Register of Controlled Trials from inception to December 2014 (Table S2 shows the search strategy used 
| Data extraction
Two reviewers, working independently, extracted data on study characteristics, interventions, patient characteristics at baseline and outcomes for the study populations of interest for the eligible studies. If discrepancies occurred between the data extracted by the 2 reviewers, these differences were reconciled by involving a third reviewer. In the event that the third reviewer could not resolve a disagreement, the authors of the publication were contacted for clarification.
Data on all outcomes were extracted as intention-to-treat analyses, where all dropouts were assumed to be treatment failures, wherever trial reporting allowed this. For studies that reported "perprotocol" results only, these were extracted and used in the analyses.
For observational studies, we focused on extracting adjusted estimates representing comparative effects through hazard ratios (HRs), odds ratios or relative risks, as intention-to-treat and per-protocol issues were not relevant.
| Study quality
For included RCTs, we assessed the validity of individual trials using the Risk of Bias instrument, endorsed by the Cochrane Collaboration. 20 This instrument is used to evaluate 6 key domains: sequence generation; allocation concealment; blinding of participants, personnel and outcome assessors; incomplete outcome data; selective outcome reporting; and other sources of bias.
For observational studies, we used the Newcastle-Ottawa scale.
With this scale, each study is judged on 8 items, categorized into 3 groups: the selection of the study groups; the comparability of the groups; and the ascertainment of either the exposure or outcome of interest for case-control or cohort studies, respectively. Stars awarded for each quality item serve as a quick visual assessment.
The same 2 reviewers extracting data conducted the quality assessment. If disagreements between the reviewers occurred, we resolved these by including a third reviewer, and if necessary, contacting the authors of the publication for clarification. No studies were excluded on the basis of quality.
| Evidence synthesis
Treatments were grouped according to drug class. First-and second- TZDs and insulins. When biguanides were used as background therapy, the intervention therapy was analysed as a monotherapy. ventions. 21 For the primary analysis of observational data, conventional fixed-effect pairwise meta-analyses were used to pool adjusted HRs for each pairwise treatment comparison.
Because the outcomes typically only occurred once, we assumed that adjusted relative risks from observational studies could be con- Because observational studies represent pragmatic clinical practice and clinical trials are controlled settings, we included observational studies to perform an external validity check for the RCT evidence.
We acknowledge that the present study was not hypothesis-testing, however, we believe that with the external validity check for the RCTs, this systematic review work will be placed between exploratory and hypothesis testing. We additionally calculated the same absolute differences in risk based on the observational data using the estimated survival function for SU and the pooled (observational)
HRs to produce survival functions for the other interventions.
We produced 2 types of forest plots to display the results graphically. The first compared the study-specific estimates provided in each study and the second compared the relative efficacies among treatments, as estimated in the analysis. In traditional meta-analysis, forest plots are used to present the results from individual studies and the synthesized result from the analysis, providing a visual assessment of the statistical heterogeneity. Statistical heterogeneity is caused by differences in factors that influence the outcome or the intervention, such as prognostic factors. As explained above, our analyses account for an important effect modifier, namely time. Longer follow-up periods lead to higher probabilities of an event occurring.
Because prescription of rosiglitazone had been limited or suspended in many countries as a result of cardiovascular safety concerns, 22 ,23 a sensitivity analysis was conducted excluding this treatment from the TZD class.
All Bayesian analyses were performed in WinBUGS v3.1.4, and all conventional meta-analyses were performed and figures produced using R v3.1.2.
3 | RESULTS Figure S1 , and the summary of baseline characteristics and quality of included studies is presented in Tables S3-S8.
| Included studies
| All-cause mortality
The results of the analysis of all-cause mortality for the RCT and observational evidence are shown in Table 1 and Figure 1A . Additionally, Figure S2 shows the forest plot for individual study results. 
| Cardiovascular-related mortality
The results of the analyses of the risk of cardiovascular-related mortality are shown in Table 1 and Figure 1B . In addition, Figure S3 
| Acute MI
The results of the analyses of the risk of acute MI are shown in Table 1 and Figure 1C . Additionally, Figure S4 shows the forest plot for the indi- Data reported are for the >1 year time point.
-, not applicable due to lack of trial data.
1 P < .001.
P < .01
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| Stroke
The results of the analyses of the risk of stroke are shown in Table 1 and Figure 1D . In addition, Figure S5 shows the forest plot for the individual study results. Several systematic reviews have addressed similar topics concerning SU therapy 9, [12] [13] [14] [15] 18, [24] [25] [26] ; however, these studies had important methodological limitations, including grouping treatments with diverse safety profiles, imprecise study inclusion criteria and nonsystematic searches, and important analytical limitations. Four of the studies reported similar results to those of the present review for allcause mortality and cardiovascular-related mortality. 12, 15, 18, 25 Two of these studies only included subsets of SUs. 9, 24 Two of the reviews were associated with methodological limitations, such as incorrect inclusions, inconsistent reporting, and lack of a rigorous search strategy. 13, 14 Furthermore, one recent review assessed cardiovascular outcomes, but this meta-analysis only included SUs and aimed to report on differences within this treatment class. 26 The most recent meta-analysis on this topic was presented by Rados et al 19 are not controlled by metformin monotherapy. 28 It is hoped that these 2 trials will be able to provide a definitive answer to the question about the cardiovascular risk of SUs when compared directly with an active comparator, a DPP-4 inhibitor or a TZD. Second, the minimal amount of data in some analyses did not allow robust effect estimates. For instance, low event counts in some comparisons resulted in wide CIs and potentially misleading large risk differences. Third, our analyses focused on class effects to ensure sufficient sample sizes to detect differences; however, it should be recognized that individual SU treatments may differ in terms of mortality risk. 26 Fourth, meta-analyses of randomized trials are not designed a priori to test a hypothesis and rather should only be considered as hypothesis-generating; however, inclusion of observational studies to validate the RCTs will place this work between exploratory and hypothesis testing. Finally, there are inherent flaws in meta-analyses, which rely on high-quality study data. The present study used a rigorous search and extraction method to ensure high-quality evidence was integrated appropriately. Risk of bias assessments were performed for both RCTs and observational studies to summarize study quality.
| Sensitivity analysis
The present meta-analysis showed an association between sulphonylurea therapy and a higher risk of cardiovascular-related events compared with other antihyperglycaemic drugs. This risk observed in RCTs was confirmed with data from the observational studies. The CAROLINA and TOSCA IT trials should have results in 2018 and will provide more definitive answers regarding the effect of sulphonylureas on cardiovascular risk relative to other antihyperglycaemic drugs.
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